While classical detection methods have been successfully used in pharmaceutical and medical device quality control for many decades, new, more sustainable analytical methods that do not rely on animal-derived materials are becoming increasingly important, driven by considerations of species conservation and animal welfare. At the same time, regulatory frameworks on both sides of the Atlantic continue to evolve, confronting companies in the pharmaceutical and medical device sectors with the challenge of developing testing strategies that are both effective and sustainable in the long term.

The integration of innovative detection methods newly entering the market also presents many companies with strategic and methodological challenges in establishing these methods in compliance with cGMP requirements.

As the range of available test methods in the field of endotoxin and pyrogen detection continues to expand, the importance of experienced laboratory partners capable of reliably applying the various technologies and providing support on analytical and regulatory matters is also increasing. In addition to analytical testing, process-critical aspects such as comprehensive methodological expertise, know-how in handling complex product matrices, and short and reliable turnaround times are becoming increasingly important. The integration of innovative detection methods newly entering the market also presents many companies with strategic and methodological challenges in establishing these methods in compliance with cGMP requirements.

In line with the 3R principles (Replace, Reduce, Refine), these methods do not rely on animal-derived materials while also reducing risks associated with vulnerable supply chains and geopolitical dependencies. 

The classical Limulus Amebocyte Lysate (LAL) test, whether performed as a qualitative or quantitative assay, remains the established gold standard for the reliable detection of bacterial endotoxins. At the same time, recombinant methods are evolving rapidly and gaining wider importance. In line with the 3R principles (Replace, Reduce, Refine), these methods do not rely on animal-derived materials while also reducing risks associated with vulnerable supply chains and geopolitical dependencies. 

A prominent example is the biotechnologically produced recombinant Factor C (rFC) assay, which is already widely used in various applications. Owing to its performance characteristics, the rFC assay has been incorporated into the European Pharmacopoeia and is recognized as equivalent to conventional LAL-based methods. Analytical methods based on Recombinant Cascade Reagents (rCR) are also attracting increasing attention and are expected to further expand the range of available recombinant endotoxin testing solutions in the near future.

When the focus is on pyrogenic substances in general rather than exclusively on bacterial endotoxins, different analytical detection methods are required.

In addition to the detection of bacterial endotoxins, non-endotoxin pyrogens also play a significant role in the quality control of pharmaceutical and medical device products. Therefore, when the focus is on pyrogenic substances in general rather than exclusively on bacterial endotoxins, different analytical detection methods are required.

A global shift from in vivo to in vitro testing methods is currently underway. In Europe, the in vitro Monocyte Activation Test (MAT) fully replaced the in vivo Rabbit Pyrogen Test (RPT) at the beginning of 2026. Comparable developments can also be observed on a global scale.

Given the complexity of analytical challenges, scientific support throughout projects is becoming increasingly important.

As the Monocyte Activation Test continues to evolve, new and innovative MAT methods are emerging. Consequently, not only is the number of available MAT methods increasing, but selecting the most appropriate testing approach is becoming increasingly challenging. Given the complexity of analytical challenges, scientific support throughout projects is becoming increasingly important. Sound expertise in MAT analytics, combined with comprehensive know-how in the implementation of new MAT methods and technologies, represents a decisive competitive advantage.

Continued advances in testing methodologies will create new opportunities in the years ahead. For manufacturers, it is therefore essential to continuously monitor technological developments and regulatory requirements in order to ensure reliable and future-proof control of pyrogenic contamination.

about the author

Enrico Barth is the Head of Examination of bacterial endotoxins at Labor LS SE & Co. KG.